Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) shares traded up 5.8% during mid-day trading on Tuesday . The company traded as high as $1.65 and last traded at $1.65. 175,365 shares changed hands during trading, a decline of 63% from the average session volume of 473,519 shares. The stock had previously closed at $1.56.
Tiziana Life Sciences Stock Up 5.8%
The stock's fifty day moving average price is $1.33 and its 200 day moving average price is $1.08.
Institutional Investors Weigh In On Tiziana Life Sciences
Several large investors have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC purchased a new stake in shares of Tiziana Life Sciences in the 1st quarter worth $25,000. Bison Wealth LLC purchased a new position in shares of Tiziana Life Sciences during the fourth quarter valued at $30,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Tiziana Life Sciences in the first quarter valued at about $156,000. Geode Capital Management LLC lifted its stake in Tiziana Life Sciences by 12.4% in the fourth quarter. Geode Capital Management LLC now owns 245,722 shares of the company's stock worth $171,000 after acquiring an additional 27,041 shares during the period. Finally, Jane Street Group LLC lifted its stake in Tiziana Life Sciences by 968.2% in the first quarter. Jane Street Group LLC now owns 167,542 shares of the company's stock worth $181,000 after acquiring an additional 151,858 shares during the period.
Tiziana Life Sciences Company Profile
(
Get Free Report)
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tiziana Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tiziana Life Sciences wasn't on the list.
While Tiziana Life Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
